Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

GlobeNewswire April 21, 2021

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

Business Wire April 21, 2021

FGEN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

ACCESSWIRE IA April 21, 2021

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile April 21, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN

Newsfile April 21, 2021

LAWSUIT FILED: FibroGen, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton

GlobeNewswire April 21, 2021

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAN, CS, DOX and FGEN

GlobeNewswire April 20, 2021

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.

Newsfile April 20, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Announces Filing of Securities Fraud Class Action

GlobeNewswire April 20, 2021

FIBROGEN INVESTOR ALERT: Shareholder Lawsuit Filed

Newsfile April 20, 2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA April 20, 2021

FGEN SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.

GlobeNewswire April 20, 2021

FGEN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Fibrogen, Inc. Shareholders

Newsfile April 20, 2021

Rosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN

Newsfile April 19, 2021

FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

Business Wire April 19, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates DOX, FGEN Investors on Securities Fraud Lawsuits, Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA April 16, 2021

FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN

Newsfile April 15, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Approaching

ACCESSWIRE IA April 15, 2021

Portnoy Law: Lawsuit Filed On Behalf of FibroGen, Inc. Investors

GlobeNewswire April 15, 2021

SHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading Shareholders

Business Wire April 15, 2021